RAZA SAIYED ATIQ 4

What Happened

• Raza Saiyed Atiq, a director of Arteris, sold a total of 70,000 shares in open-market transactions on July 1, 2026, generating approximately $3,176,980 in proceeds. The reported line items:
  • 20,959 shares at a weighted average price of $46.20 — $968,279 (prices ranged $45.68–$46.67)
  • 26,138 shares at a weighted average price of $43.98 — $1,149,539 (prices ranged $43.68–$44.67)
  • 9,270 shares at a weighted average price of $44.99 — $417,042 (prices ranged $44.68–$45.64)
  • 13,633 shares at a weighted average price of $47.10 — $642,120 (prices ranged $46.68–$47.63)
• These were sales (S), which are generally routine dispositions rather than an explicit bullish signal.

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 2, 2026 (timely filing).
• Total shares sold: 70,000; Total reported proceeds: ~$3.18 million.
• Filing notes the trades were made pursuant to a 10b5-1 trading plan adopted November 7, 2025.
• Reported prices are weighted averages; the filing provides price ranges for the multiple executions and offers to disclose per-price breakdowns on request.
• The filing indicates some shares are held in the "Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust," for which he serves as trustee.
• Transaction code: S = Sale.

Context

• Sales executed under a pre-established 10b5-1 plan are typically scheduled in advance to avoid trading on material, nonpublic information; they are common for insiders who wish to diversify or access liquidity.
• The filing is factual and does not state the insider’s motivation. Purchases generally carry stronger signals about insider sentiment than routine, pre-planned sales.